Skip to Content

Eylea Approval History

  • FDA approved: Yes (First approved November 18th, 2011)
  • Brand name: Eylea
  • Generic name: aflibercept
  • Dosage form: Injection
  • Company: Regeneron Pharmaceuticals, Inc.
  • Treatment for: Macular Degeneration, Macular Edema

Eylea (aflibercept) is a VEGF inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Development History and FDA Approval Process for Eylea

Mar 25, 2015Approval FDA Approves Eylea (aflibercept) for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Jul 29, 2014Approval Eylea (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema
Nov 18, 2011Approval FDA Approves Eylea for Wet Age-Related Macular Degeneration
Aug 17, 2011Regeneron Announces Review of Biologics License Application for Eylea (aflibercept injection) Extended by Three Months by FDA
Jun 17, 2011Regeneron Announces Eylea (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.